|
Nephrology in Spain |
 |
INFORMATION OF THE GEENDIAB |
|
GEENDIAB is a group born in January 1995, as a working Group of Spanish Society of Nephrology (S.E.N.).
The current 67 members of the group are listed in the "Anexo 1" and are widespread around the Spanish geography (delegates from many of the level I, II and III Spanish Hospitals).
The first end-point of the Group was to establish the hallmark and rules of the Group, into the organization of the SEN.
GEENDIAB promoted the first "Consensus Document on Detection, Prevention and Treatment of Diabetic Nephropathy in Spain", which was accepted by four Societies (SEN, SEE&N, - Spanish Society of Endocrinology & Nutrition-, SEDIAB, - Spanish Society of Diabetes- and SEMFYC, -Spanish Society of Family and Community Medicine-). The Document was published in the four official publications of the respective Societies in1997.
The second important end-point was the CALVIDIA study. This was a multicenter study which aimed to compare the characteristics of the diabetic patient starting dialysis (haemo or peritoneal dialysis) with the non-diabetic patient. The initials CALVIDIA stand for "Quality of Life of Diabetic patients" , in spanish "Calidad de Vida del diabético". This prospective observational study has been finished and submitted to "Diabetes Care" for evaluation for publication.
GEENDIAB has also designed the EPODIAB study, on the "Treatment of anemia in diabetic patient". This has been a Spanish multicentre study performed in 14 hospitals, which has included 136 type 2 diabetic patients with established nephropathy and progressive renal failure. Ninety-six patients were treated with subcutaneous r-Hu-EPO alfa and have completed 12 months follow-up. The study is now pending of publication.
In the last year another multicentre study has been carried out. It was the DAFNE study, designed as a clinical trial on the treatment of Arterial Hypertension in type 2 diabetic patients with hypertension and established nephropathy. The patients were treated with an ACEI, quinapril, and randomized to receive hydrocholorothyazide or doxazosin GITS (Gastrointestinal therapeutic system). Out of the 101 included patients, seventy-six were randomized and completed the follow-up period. In the next months the data will be available.
In 2002 GEENDIAB promoted the re-evaluation of the 1997´s Diabetic Nephropathy Consensus Document. Three new Societies were claimed and added to the four initial ones: The SEH-LELHA (Spanish Hypertension Society and Fight against High Blood Pressure), SEMERGEN (Spanish Rural and General Medicine Society) and AENP (Pediatric Spanish Association). The new revised document was published in the seven official publications at the respective Societies.
The last multicenter study promoted by GEENDIAB is the MIRENA study. It is a study on the morbidity and mortality factors affecting the diabetic patient with progressive renal failure not yet into dialysis, compared with the non-diabetic patient in the same pre-dialysis situation. The study is currently starting and the expected follow-up will last three years. We estimate in 800 the number of patients to be included.
 |
